CancerCompass is dedicated to provided you with the most up to date cancer information and news. Visit our website to find all our articles on Other Cancer News http://www.cancercompass.com/other-cancer-news.htm Sat, 21 Nov 2009 00:00:00 GMT Sat, 21 Nov 2009 00:00:00 GMT http://backend.userland.com/rss RSS.NET: http://www.rssdotnet.com/ Synta Pharmaceuticals Corp, a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a novel, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated strong activity in multiple tumor models. http://www.cancercompass.com/cancer-news/article/32436.htm CancerCompass Thu, 19 Nov 2009 00:00:00 GMT U.S. health experts say about two-thirds of cancers could be prevented via lifestyle changes. The Mayo Clinic researchers explain in their Special Report on Cancer Prevention in the November issue of Mayo Clinic Women's HealthSource says maintaining proper weight by eating a healthy, low-fat diet and by stepping up moderate to vigorous physical activity to 45 to 60 minutes almost daily might reduce one- third of cancer deaths. http://www.cancercompass.com/cancer-news/article/32421.htm CancerCompass Tue, 17 Nov 2009 00:00:00 GMT When the pain in her knee from an old running injury continued even after surgery, Sarah McCluan turned to the Internet for help. I don't use it to diagnose ,but I do go to the Internet for basic information," said McCluan, who downloaded some knee strengthening exercises that she is following. McCluan, 37, of Hopewell is among a growing number of wired adults searching the Internet for medical information. http://www.cancercompass.com/cancer-news/article/32422.htm CancerCompass Tue, 17 Nov 2009 00:00:00 GMT The American Society of Clinical Oncology (ASCO) has once again recognized Erbitux(R) (cetuximab) as one of the major clinical cancer advances of 2009. This year Erbitux was selected by ASCO for providing the first significant increase in survival for 30 years in the treatment of patients with 1st-line recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). http://www.cancercompass.com/cancer-news/article/32429.htm CancerCompass Tue, 17 Nov 2009 00:00:00 GMT Oncolytics Biotech Inc. today announced that a poster presentation covering updated results of a Phase I/II U.K. trial (REO 011) of REOLYSIN (R) combined with paclitaxel/carboplatin for patients with advanced cancers will be presented on November 17, 2009 at the 2009 AACR- NCI-EORTC Molecular Targets and Cancer Therapeutics conference being held in Boston, Massachusetts. http://www.cancercompass.com/cancer-news/article/32430.htm CancerCompass Tue, 17 Nov 2009 00:00:00 GMT According to recent research published in the journal Oncology Reports, "Laryngeal carcinoma is a malignancy of the respiratory tract with a significantly higher male to female ratio, suggesting involvement of gender-depended factors in the pathogenesis. http://www.cancercompass.com/cancer-news/article/32395.htm CancerCompass Sat, 14 Nov 2009 00:00:00 GMT A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer. http://www.cancercompass.com/cancer-news/article/32410.htm CancerCompass Sat, 14 Nov 2009 00:00:00 GMT Several components of the Writ signaling cascade have been shown to function either as tumor suppressor proteins or as oncogenes in multiple human cancers, underscoring the relevance of this pathway in oncogenesis and the need for further investigation of Wnt signaling components as potential targets for cancer therapy. http://www.cancercompass.com/cancer-news/article/32411.htm CancerCompass Sat, 14 Nov 2009 00:00:00 GMT The dismal outcome of esophageal cancer patients highlights the need for novel prognostic biomarkers, such as microRNAs (miRNA). http://www.cancercompass.com/cancer-news/article/32416.htm CancerCompass Sat, 14 Nov 2009 00:00:00 GMT A study featured in the November issue of the Journal of Thoracic Oncology confirms the success of a simple questionnaire designed to identify patients at high risk of lung cancer. Initiated in 2001, the current study confirmed 18 cases of cancer of the original 430 patients who qualified as high risk after completing a five-minute questionnaire. http://www.cancercompass.com/cancer-news/article/32417.htm CancerCompass Sat, 14 Nov 2009 00:00:00 GMT Research published in the November 2009 issue of the Journal of Thoracic Oncology has found that intervals between lung cancer suspicion, diagnosis and treatment may be attributed to health care system discrepancies. http://www.cancercompass.com/cancer-news/article/32419.htm CancerCompass Sat, 14 Nov 2009 00:00:00 GMT Patients with locally advanced esophageal cancer who require neoadjuvant therapy have significant dysphagia. To prospectively evaluate Polyflex stents to treat malignant dysphagia and to ameliorate weight loss in patients with locally advanced esophageal cancer who will undergo neoadjuvant therapy, scientists in the United States report. http://www.cancercompass.com/cancer-news/article/32427.htm CancerCompass Tue, 17 Nov 2009 00:00:00 GMT Current study results from the report, 'A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma,' have been published. According to a study from the United Kingdom, Platinum compounds, taxanes and anthracyclines provide the major effective drug classes in the treatment of advanced and recurrent endometrial cancer and carcinosarcoma. http://www.cancercompass.com/cancer-news/article/32431.htm CancerCompass Tue, 17 Nov 2009 00:00:00 GMT The development of stomach cancer is closely associated with chronic inflammation, and the Wnt/beta-catenin signaling pathway is activated in most cases of this cancer. High-mobility group A (HMGA) proteins are oncogenic chromatin factors that are primarily expressed not only in undifferentiated tissues but also in various tumors, scientists writing in the American Journal of Pathology report. http://www.cancercompass.com/cancer-news/article/32432.htm CancerCompass Tue, 17 Nov 2009 00:00:00 GMT According to recent research from the United States, Radiosurgery for brain metastasis fails in some patients, who require further surgical care. In this paper the authors' goal was to evaluate prognostic factors that correlate with the survival of patients who require a resection of a brain metastasis after stereotactic radiosurgery (SRS). http://www.cancercompass.com/cancer-news/article/32433.htm CancerCompass Tue, 17 Nov 2009 00:00:00 GMT NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding. http://www.cancercompass.com/cancer-news/article/32382.htm CancerCompass Tue, 10 Nov 2009 00:00:00 GMT When it comes to vitamin D, consumers are bombarded with mixed messages about the best source for this essential nutrient. While some may argue that small doses of intentional sun exposure are safe, dermatologists point out that the risk of developing skin cancer from ultraviolet (UV) radiation far outweighs the benefit of stimulating vitamin D production - particularly when enriched foods and supplements are safe and effective sources of this vitamin. http://www.cancercompass.com/cancer-news/article/32385.htm CancerCompass Tue, 10 Nov 2009 00:00:00 GMT U.S. scientists say a rapid decline in metabolic activity on a PET scan after radiation for non- small cell lung cancer suggests good local tumor control. http://www.cancercompass.com/cancer-news/article/32386.htm CancerCompass Tue, 10 Nov 2009 00:00:00 GMT U.S. medical scientists say it might be possible to identify the survival chances of advanced melanoma patients by analyzing their genetic activity. Researchers at New York University's Langone Medical Center said although the chances of surviving advanced melanoma aren't very good with current therapies, some patients can live for years with cancer that has spread beyond the skin to other organs. http://www.cancercompass.com/cancer-news/article/32388.htm CancerCompass Tue, 10 Nov 2009 00:00:00 GMT A new U.S. study has shown that green tea may help reduce the risk of oral cancer, although scientists are reluctant to officially endorse green tea as an effective way of cancer prevention. http://www.cancercompass.com/cancer-news/article/32387.htm CancerCompass Tue, 10 Nov 2009 00:00:00 GMT